Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

Ähnliche Einträge

• Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
  von: William Townsend, et al.
  Veröffentlicht: (2023-07-01)
• Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
  Veröffentlicht: (2022-06-01)
• S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY
  von: W. Townsend, et al.
  Veröffentlicht: (2022-06-01)
• A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
  von: Laurie H. Sehn, et al.
  Veröffentlicht: (2020-06-01)
• Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
  von: Andrew Grigg, et al.
  Veröffentlicht: (2017-04-01)